The European Medicines Agency (EMEA), European CDC, and the Heads of Medicines 
Agencies (HMA) established a document regarding the monitoring of the benefits and risks of H1N1 vacines in relation to the safety and effectivenes of the vaccines.
The document covers materials such as Influenza A (H1N1) vaccines safety and effectiveness, the immunogenicity, benefit-risk evaluation, vaccine manufacturers, the vaccines authorised, research, clinical and public health centres, components of strategies in monitoring the benefit-risk A/H1N1 vaccines, and the funding mechanisms in relation to the overall benefit-risk assesment.
For detailed article about Influenza A (H1N1) Vaccine Risk-Benefit Monitoring in Europe, please refer to the following medical H1N1 article (source: emea.europa.eu).
